BioFluidica, a US-based privately held biotechnology company, announced on Friday that it planning to commercialise the LiquidScan Automated Liquid Biopsy System, a high throughput rare biomarker (circulating tumour cells, exosomes, and cell-free DNA) enrichment solution.
The company has designed and developed an automation-ready liquid biopsy instrument compatible with Hamilton Robotics Microlab STAR series liquid handlers. The commercial version of the LiquidScan system is produced under present Good Manufacturing Practices and includes complete documentation to facilitate clinical application development and clinical trials under EUA and FDA guidelines.
BioFluidica is offering a limited number of systems to certain Core facilities in North America through Early Technology Access Program from fourth quarter of 2021.
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application
Polarean expands Ascend Imaging partnership to boost US market reach